. In the 1980s, strain B:4:P1.15 (ET-5 complex) caused outbreaks in during the immediate preepidemic years, 1989 and 1990, was 1.5/100,000 population. In 1996, a rate of 14.0/100,000 populaCuba [7] and Brazil [8] , and Chile experienced an outbreak of disease involving B:15:P1.3 [9] . The recent increase in serotion was reached. Highest rates of disease, in 1996, occurred in children õ5 years with rates of 142/100,000 in those õ1 group B disease in the Pacific Northwest of the United States also involved strains of the ET-5 complex [10] .
year of age and 72.9/100,000 in children 1 -4 years old (table  1) . A second small peak in incidence occurred in young adults, A newly identified clone with phenotype B:4:P1.4, ET-24 (lineage III), was encountered in The Netherlands in the early aged 15 -19 years. However, rates for all age groups were significantly elevated compared with those for the 1989 -1990 1980s [11] . We describe the first 6 years, 1991 -1996 (inclusive), of a continuing epidemic of meningococcal disease in period. Ethnic differences in rates were most pronounced in those õ1 year with rates, in 1996, of 549.6/100,000 in Pacific New Zealand, which has involved the increased incidence of a strain with phenotype B:4:P1.4 and which belongs to linIslands infants, 150.1/100,000 in Maori infants, and 73.7/ 100,000 in European infants. Annually, a winter-spring seaeage III.
sonal peak in case numbers occurred. The case-fatality rate has remained at Ç5%.
Materials and Methods
Most disease has been confirmed by the isolation of N. meningitidis from a normally sterile site, but since 1994, the number predominated. In 1996, it represented 72.9% of all serogroup Genetic typing. Macrorestriction analysis of 667 invasive iso-B isolates identified. Each year, some isolates have not been lates using SfiI and Nhe was based on the method of Bygraves and serotypeable although they have expressed the PorA P1.4 antiMaiden [5] . Chromosomal DNA (Saccharomyces cerevisiae) was gen. In 1995 and 1996, these accounted for about 12% of used in gels as a band migration size reference, and restricted DNA serogroup B isolates. Annually a few isolates (õ3%) with from a local isolate was used to control pattern reproducibility. ET Genotypic characterization. Three restriction fragment resistant, serogroup B strain with phenotype B:15:P1.7,16 and of the ET-5 complex, also caused a cluster of cases among length polymorphism analysis (RFLP) patterns, designated types 1, 3, and 4, varying only in size and therefore position university students in 1992 [12] . Among the serogroup C meningococci, serotype 2b has predominated. Isolates with phenoof one or two of the fragments, represented 63%, 14%, and 12%, respectively, of all serogroup B meningococci with the type C:2b:P1. (5) disease prior to 1991 [12] . The background incidence during 1989 -1990 was similar to that reported in other ''westernized'' Cases of disease caused by the outbreak strain, B:4:P1.4, have occurred sporadically throughout New Zealand, with no countries and showed the same characteristics, with a higher disease incidence in preschool children and a dominance of obvious geographic focus. Secondary cases among all age groups have been recorded. Additionally, a small number of serogroup B disease. Since 1990, rates have been markedly higher than those of other industrialized countries, including clusters involving teenage and young adult groups, particularly associated with educational facilities, has been documented. our closest neighbor, Australia, where incidence rates of 1.6 -2.2/100,000 were recorded in 1991 -1994 [14] . During the epidemic, a phenotypically distinct, sulfonamide- and peak incidence in winter and early spring.
Some clustering of cases involving meningococci of B:4:P1.4 has occurred among students indirectly linked through educational facilities [12] . The sulfonamide-resistant strain,
